CYP2G1P

Across TCGA pan-cancer cohorts, CYP2G1P mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of CYP2G1P’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where CYP2G1P mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CYP2G1P is over-expressed in tumor.

CCRCC, HNSC, and PDAC are the cancer types where CYP2G1P tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CYP2G1P mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	+1.194	<.001	12	view →
HNSC	Male	All	+1.240	<.001	11	view →
PDAC	Female	II,III,IV	+1.175	<.001	8	view →
LSCC	Male	II,III,IV	+0.838	<.001	8	view →
LUAD	Male	All	+0.416	<.001	7	view →
COAD	All	All	+0.432	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

CYP2G1P–CCRCC

Open the CCRCC breakdown →